Physician profile
Christopher Mesa
NPI 1598150542
$198,335.93
in general payments reported to CMS, 2019-2025
24 companies · $54K in 2025
The $54K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,381 · 2020: $683 · 2021: $1,781 · 2022: $5,909 · 2023: $48K · 2024: $86K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Honoraria: $31K · Travel and Lodging: $28K · Consulting Fee: $19K · Food and Beverage: $10K · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100,447.50 |
| Honoraria | $31,162.50 |
| Travel and Lodging | $27,585.52 |
| Consulting Fee | $18,772.50 |
| Food and Beverage | $10,348.94 |
| Education | $263.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $115,291.64 | 2019-2025 | Krystexxa, Uplizna, Otezla |
| Horizon Therapeutics Plc | $36,721.98 | 2022-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $17,851.39 | 2019-2025 | Cosentyx |
| Genzyme Corporation | $14,696.99 | 2023-2025 | |
| Janssen Biotech, INC. | $7,839.65 | 2019-2024 | Tremfya, Stelara |
| Pfizer INC. | $2,455.34 | 2019-2024 | |
| Abbvie INC. | $1,549.48 | 2019-2023 | |
| Glaxosmithkline, LLC. | $531.20 | 2019-2024 | Benlysta |
| Janssen Scientific Affairs, LLC | $466.09 | 2019-2025 | Tremfya |
| Ucb, INC. | $180.64 | 2020-2023 | Cimzia |
| Mallinckrodt Hospital Products INC. | $177.88 | 2022-2023 | Acthar |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2021 | |
| Genentech USA, INC. | $124.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Lilly USA, LLC | $63.49 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29.41 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $22.43 | 2022 | |
| Sandoz INC. | $22.17 | 2023 | Hyrimoz |
| Ani Pharmaceuticals, INC. | $19.63 | 2023 | Purified Cortrophin Gel |
| Sanofi Pasteur INC. | $15.72 | 2019 | |
| Bioventus LLC | $15.12 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $14.92 | 2019 | |
| Aurinia Pharma U.S., INC. | $13.73 | 2022 | |
| Qiagen, LLC | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mesa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.